Forte Biosciences, Inc.
FBRX
$11.16
-$0.10-0.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.72% | -36.00% | -12.71% | -12.18% | -49.45% |
| Total Depreciation and Amortization | 71.43% | 138.89% | 333.33% | 1,066.67% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 38.78% | 14.41% | -6.85% | -1.27% | -12.63% |
| Change in Net Operating Assets | -117.94% | 611.17% | 548.21% | -72.51% | -58.23% |
| Cash from Operations | -25.88% | -14.13% | -7.10% | -31.26% | -97.46% |
| Capital Expenditure | 2.13% | 2.13% | 57.95% | 67.61% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -96.10% | 191.85% | -26,734.07% | -99.25% | 201.35% |
| Cash from Investing | -96.98% | 636.59% | -76,680.85% | -134.92% | 200.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 411.70% | 111.91% | 111.92% | -99.10% | 243.18% |
| Repurchase of Common Stock | 56.45% | 55.26% | 41.67% | 56.31% | 21.52% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,873.53% | -1,163.97% | -312.50% | -- | -274.36% |
| Cash from Financing | 385.75% | 100.82% | 110.08% | -100.38% | 235.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,910.99% | 382.37% | -274.36% | -1,495.51% | 122.42% |